Want news about Cipla to land in your mailbox?


Morgan Stanley underweight on Cipla; target Rs 195
Morgan Stanley has recommended underweight rating on Cipla with target price of Rs 195. The company appeared optimistic on its longer-term growth prospects, as underlined by the hefty USD 250 million capex plan over next two years.
Morgan Stanley report on Cipla:
We attended Cipla’s AGM, a once-a-year opportunity to interact with management, and found the team in communicative mood.
|
Also Read
RSS feed for news |
Central message
The company appeared optimistic on its longer-term growth prospects, as underlined by the hefty USD 250 million capex plan over next two years. It cautioned that the profits could de-grow in the current year (we are at flat earnings). Cipla mentioned that it is increasingly difficult to grow sales off a high base (Rs 36 billionn F07 sales), and guides for 10-12% sales growth for F2008-09. It is planning a USD 100 million ECB issue. We maintain our Underweight rating on the stock in view of the ongoing earnings deceleration and expect 1-2 more tough quarters ahead.
HFA inhaler pipeline increasing.
Cipla highlighted its HFA inhaler pipeline for the EU markets – 8 products, of which 6 have been filed (2 approved), for which it will get approvals in the ensuing quarters in EU. Budesonide has been approved in Germany, Portugal and Spain; salbutamol in Denmark (UK, Spain and Portugal likely in F08). Cipla is also developing these products for the US market, though launch prospects are distant.
Building technology-intensive portfolio, but US/EU commercialization appears at least 2-3 years away. The company has launched its proprietary transdermal patch for testosterone and estradiol in India; inhaled insulin launch in India is expected soon; and it is building a pipeline of 11 biosimilars in partnership with Avesthagen
Generic Advair launch in UK (USD 300 million mkt) could happen in early 2009 (clinicals done, regulatory submission not done), according to Cipla. Cipla, Ivax, Arrow and Generics UK had earlier (2004) invalidated 2013 combination patent. It is awaiting approval of generic Flonase for its partner for the US launch. US tie-ups span 10 players, 91 ANDAs filed, another 20-25 filings and 10 more launches in F08.


Business
Business News | Economy | Earnings | BSE NSE Notices
General News
Current Affairs | Politics | World News | Sports | Entertainment
Corporate Strategy
Management | Advertising | Marketing | Legal
Personal Finance
Tax | Insurance | Credit Cards | Loans | Property | Retirement | Investment Help | Financial Planning | Fixed Income
Markets
Local Market | Global Market | Market Cues | Analysis | Expert & FII outlook | Brokerage Recomendation
Stocks
Stocks in News | Expert Advice | ADRs & GDRs | IPO
Mutual Funds
News | Advice | MF Analysis | Fund Managers Views
Lifestyle
Travel | Wellness | Technology | Auto| Books
Harsh Manglik
Chairman
Accenture India
Accenture India to hire aggressively for select verticals
Vishal Doshi
Managing Director
Shrenju & Company
Shrenuj & Company will project 15% rev rise this yr
MP Taparia
Chairman
Supreme Petrochemicals
Supreme Petrochemicals expects Rs 2200cr rev in next 1.5yrs
Vineet Nayyar
Chief Executive Officer
HCL Technologies
HCL Tech plans to merge arms with itself, eyes new spots
-
Most Read
-
Most Viewed
- UBS Sec: Good level to enter mkts, suggests stocks

- Mitesh Thacker's top 5 picks for today's trade

- Nifty to cross 5100; infra, banking best bets: Quantum Sec

- End of BPLR: RBI to de-regulate lending rates in FY11

- ARSS Infrastructure IPO opens; should you subscribe?
- Jubilant Food's anchor investors buy add'l stake on debut
- SAIL to issue bonus shares before FPO: Sources

- Ten success stories in unheard of sectors
- What is Religare Capital betting on in the long-term?

- India a stock picker's market: JPMorgan Sec

- China confirmed as global export champion
Source: ft.com
- Time to understand how the mighty fall
Source: ft.com
- India growth set to near 2007 boom levels
Source: ft.com
- Speculators build record bets against euro
Source: ft.com













